430 related articles for article (PubMed ID: 34071155)
1. Fc-Receptor Targeted Therapies for the Treatment of
Keller CW; Pawlitzki M; Wiendl H; Lünemann JD
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155
[No Abstract] [Full Text] [Related]
2. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.
Gable KL; Guptill JT
Front Immunol; 2019; 10():3052. PubMed ID: 31998320
[TBL] [Abstract][Full Text] [Related]
4. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
Dalakas MC
Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
[TBL] [Abstract][Full Text] [Related]
5. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis.
Dalakas MC
Expert Rev Clin Immunol; 2022 Jul; 18(7):691-701. PubMed ID: 35730504
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.
Liu L; Garcia AM; Santoro H; Zhang Y; McDonnell K; Dumont J; Bitonti A
J Immunol; 2007 Apr; 178(8):5390-8. PubMed ID: 17404325
[TBL] [Abstract][Full Text] [Related]
7. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.
Wolfe GI; Ward ES; de Haard H; Ulrichts P; Mozaffar T; Pasnoor M; Vidarsson G
J Neurol Sci; 2021 Nov; 430():118074. PubMed ID: 34563918
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
9. Conventional and emerging treatments and controversies in myasthenia gravis.
Evoli A; Damato V
Expert Rev Neurother; 2023 May; 23(5):445-456. PubMed ID: 37102669
[TBL] [Abstract][Full Text] [Related]
10. [Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].
Murai H; Harada D
Brain Nerve; 2024 Feb; 76(2):183-191. PubMed ID: 38351566
[TBL] [Abstract][Full Text] [Related]
11. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
12. Neonatal Fc Receptor-Targeted Therapies in Neurology.
Nelke C; Spatola M; Schroeter CB; Wiendl H; Lünemann JD
Neurotherapeutics; 2022 Apr; 19(3):729-740. PubMed ID: 34997443
[TBL] [Abstract][Full Text] [Related]
13. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
14. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.
Mané-Damas M; Molenaar PC; Ulrichts P; Marcuse F; De Baets MH; Martinez-Martinez P; Losen M
Autoimmun Rev; 2022 Jul; 21(7):103104. PubMed ID: 35452851
[TBL] [Abstract][Full Text] [Related]
15. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
16. [Myasthenia in adults, children, and adolescents: what's new?].
Stascheit F; Della Marina A; Meisel A
Nervenarzt; 2023 Jun; 94(6):501-509. PubMed ID: 36995386
[TBL] [Abstract][Full Text] [Related]
17. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
18. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
19. Disorders affecting the acetylcholine receptor: myasthenia gravis and congenital myasthenia.
Vincent A
J Recept Res; 1987; 7(1-4):599-616. PubMed ID: 2442386
[TBL] [Abstract][Full Text] [Related]
20. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G; Putko BN; Wagner AN; Siddiqi ZA
Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
